Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial

Authors: Polonsky, William H., Giorgino, Francesco, Rosenstock, Julio, Whitmire, Katherine, Lew, Elisheva, Coudert, Mathieu, Alvarez, Agustina, Nicholls, Charlie, McCrimmon, Rory J.

Source: Diabetes, obesity & metabolism. 24(12):2364-2372

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100163347933.0x000001&indx=1&recIds=ETOCvdc_100163347933.0x000001

Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study

Authors: Bailey, Timothy S., Gill, Jasvinder, Jones S., Merwyn, Shenoy, Laxmi, Nicholls, Charlie, Westerbacka, Jukka

Source: Diabetes, obesity & metabolism. 24(8):1617-1622

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155256008.0x000001&indx=1&recIds=ETOCvdc_100155256008.0x000001

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?

Authors: Mauricio, Dídac, Westerbacka, Jukka, Nicholls, Charlie, Wu, Jasmanda, Gupta, Rishab, Eliasson, Björn

Source: Diabetes, obesity & metabolism. 23(3):838-843

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121426303.0x000001&indx=1&recIds=ETOCvdc_100121426303.0x000001

Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model

Authors: Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Alsaleh, Abdul Jabbar Omar, Gill, Jasvinder, Nicholls, Charlie

Source: Diabetic medicine. 40(9)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190300766.0x000001&indx=1&recIds=ETOCvdc_100190300766.0x000001

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study

Authors: Escalada, Javier, Bonnet, Fabrice, Wu, Jasmanda, Bonnemaire, Mireille, Gupta, Shaloo, Cambron-Mellott, Janelle M., Nicholls, Charlie, Müller-Wieland, Dirk

Source: Advances in therapy. 37(9):3863-3877

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100174310187.0x000001&indx=1&recIds=ETOCvdc_100174310187.0x000001

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study

Authors: Sullivan, Sean D., Nicholls, Charlie J., Gupta, Rishab A., Menon, Arjun A., Wu, Jasmanda, Westerbacka, Jukka, Bosnyak, Zsolt, Frias, Juan P., Bailey, Timothy S.

Source: Diabetes, obesity & metabolism. 21(9):2123-2132

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100086169414.0x000001&indx=1&recIds=ETOCvdc_100086169414.0x000001

Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

Authors: Sullivan, Sean D., Freemantle, Nick, Gupta, Rishab A., Wu, Jasmanda, Nicholls, Charlie J., Westerbacka, Jukka, Bailey, Timothy S.

Source: Endocrinology, diabetes & metabolism. 5(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100138904022.0x000001&indx=1&recIds=ETOCvdc_100138904022.0x000001

Real-world outcomes in people with type 2 diabetes (PWD2) and renal impairment receiving insulin glargine 300 U/mL (Gla-300) and insulin degludec 100U/mL or 200U/mL (IDeg): the DELIVER-R study

Authors: Bailey, Timothy, Urquhart, Scott, Westerbacka, Jukka, Gill, Jasvinder, Nicholls, Charlie

Source: Metabolism, clinical and experimental. 128(S)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100157971133.0x000001&indx=1&recIds=ETOCvdc_100157971133.0x000001

An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.

Authors: Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Alsaleh, Abdul Jabbar Omar, Gill, Jasvinder, Nicholls, Charlie

Source: Diabetic Medicine; May2024, Vol. 41 Issue 5, p1-8, 8p

Subject Terms: QUALITY-adjusted life years, COST effectiveness, SECONDARY analysis, INSURANCE, RESEARCH funding, INSULIN derivatives, COST analysis, TREATMENT effectiveness, TYPE 2 diabetes, RESEARCH, MEDICAL care costs, EVALUATION, DISEASE complications

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting

Authors: Zhou, Fang L., Nicholls, Charlie, Xie, Lin, Wang, Yuexi, Vaidya, Neel, Meneghini, Luigi F.

Source: Endocrinology, diabetes & metabolism. 2(3)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100085037503.0x000001&indx=1&recIds=ETOCvdc_100085037503.0x000001

Characterization of Real-World Chronic Graft-Versus-Host-Disease Patients Receiving Belumosudil

Authors: Gergis, Usama, Nicholls, Charlie ^*, Potukuchi, Praveen ^*, Kabadi, Shaum M, Verma, Deepika ^*, Patel, Nayan ^*, Li, Olivia ^*, Milgroom, Andrew ^*, Skaar, Jeffrey R ^*, Ieyoub, Jonathan ^*

Source: In Blood 15 November 2022 140 Supplement 1:12869-12870

Real-World-Ergebnisse der Zugabe von Insulin glargin 300 E/ml (Gla-300) zur GLP-1RA-Therapie bei Menschen mit Typ-2-Diabetes (T2D): Die DELIVER-G-Studie. (German)

Authors: Bailey, Timothy, Blüher, Matthias, Westerbacka, Jukka, Nicholls, Charlie, Gill, Jasvinder, Merwyn, Jones S, Shenoy, Laxmi

Source: Diabetologie und Stoffwechsel; 2022 Supplement, Vol. 17, pS46-S47, 2p

P-0238 - Real-World Management, Resource Use, Toxicity and Outcomes of Patients with Metastatic Colorectal Cancer Receiving 2nd-Line Irinotecan in the UK

Authors: Saha, Antonio, Mullamitha, Saifee, Adams, Richard, Roy, Rajarshi, Nicholls, Charlie, Dew, Robert, Glynne-Jones, Rob

Source: In Annals of Oncology June 2013 24 Supplement 4:iv103-iv103

This result is not displayed to guests.
Login for full access.

747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial.

Authors: POLONSKY, WILLIAM H., MCCRIMMON, RORY J., WHITMIRE, KATHERINE H., GIORGINO, FRANCESCO, CHEN, JUNG-FU, NICHOLLS, CHARLIE, LEW, ELISHEVA, ALVAREZ, AGUSTINA, COUDERT, MATHIEU, ROSENSTOCK, JULIO

Source: Diabetes; 2021 Supplement 1, Vol. 70, pN.PAG-N.PAG, 1p

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study.

Authors: BAILEY, TIMOTHY S., WESTERBACKA, JUKKA, NICHOLLS, CHARLIE, GILL, JASVINDER, JONES S, MERWYN, SHENOY, LAXMI

Source: Diabetes; 2021 Supplement 1, Vol. 70, pN.PAG-N.PAG, 1p

135-LB: The Forgotten Populations: Real-World Patients with T2DM Not Meeting Eligibility Criteria of the Glargine 300 U/mL EDITION and BRIGHT RCTs.

Authors: MAURICIO, DIDAC, WESTERBACKA, JUKKA, NICHOLLS, CHARLIE, WU, JASMANDA, GUPTA, RISHAB, MENON, ARJUN A., ELIASSON, BJORN

Source: Diabetes; 2019 Supplement, Vol. 68, pN.PAG-N.PAG, 1p

133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk).

Authors: SULLIVAN, SEAN D., FREEMANTLE, NICK, MENON, ARJUN A., GUPTA, RISHAB, WU, JASMANDA, NICHOLLS, CHARLIE, WESTERBACKA, JUKKA, BAILEY, TIMOTHY S.

Source: Diabetes; 2019 Supplement, Vol. 68, pN.PAG-N.PAG, 1p

Which of the 2018 Grand Tours was your favourite?

Authors: Nicholls, Charlie, Hearne, David, Ellis, Daniel, Miller, Andy, Hoare, Susan, Lester, Alaric, Hill, Andrew, Mckechnie, Graham

Source: Cycling Weekly; 12/13/2018, Issue 50, p18-18, 1p, 1 Color Photograph